Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
Silo Pharma (Nasdaq: SILO) has filed a patent application with the USPTO for SPC-14, an intranasal Alzheimer's disease treatment exclusively licensed from Columbia University. The patent, titled 'Compositions and Methods for the Treatment of Alzheimer's Disease and Other Neurogenerative Disease,' covers the drug's novel mechanism targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms.
The compound has demonstrated efficacy against luteinizing hormone in reducing learned helplessness, perseverative behavior, and hyponeophagia in early pre-clinical studies. SPC-14 was developed through a sponsored research agreement with Columbia University, followed by an exclusive global license agreement in 2024 for development, manufacturing, and commercialization rights.
Silo Pharma (Nasdaq: SILO) ha presentato una domanda di brevetto presso l'USPTO per SPC-14, un trattamento intranasale per l'Alzheimer concesso in licenza esclusiva dalla Columbia University. Il brevetto, intitolato "Composizioni e Metodi per il Trattamento della Malattia di Alzheimer e di Altre Malattie Neurodegenerative," riguarda il nuovo meccanismo d'azione del farmaco che agisce sui recettori del glutammato NDMAR e della serotonina 5-HT4 per contrastare i sintomi cognitivi e neuropsichiatrici.
Il composto ha mostrato efficacia contro l'ormone luteinizzante nel ridurre l'impotenza appresa, il comportamento perseverativo e l'iponeofagia in studi preclinici iniziali. SPC-14 è stato sviluppato tramite un accordo di ricerca sponsorizzata con la Columbia University, seguito da un accordo di licenza globale esclusiva nel 2024 per i diritti di sviluppo, produzione e commercializzazione.
Silo Pharma (Nasdaq: SILO) ha presentado una solicitud de patente ante la USPTO para SPC-14, un tratamiento intranasal para la enfermedad de Alzheimer licenciado exclusivamente por la Universidad de Columbia. La patente, titulada "Composiciones y Métodos para el Tratamiento de la Enfermedad de Alzheimer y Otras Enfermedades Neurodegenerativas," cubre el novedoso mecanismo del fármaco que actúa sobre el receptor de glutamato NDMAR y la serotonina 5-HT4 para abordar los síntomas cognitivos y neuropsiquiátricos.
El compuesto ha demostrado eficacia contra la hormona luteinizante para reducir la indefensión aprendida, el comportamiento perseverativo y la hiponeofagia en estudios preclínicos tempranos. SPC-14 fue desarrollado mediante un acuerdo de investigación patrocinada con la Universidad de Columbia, seguido de un acuerdo de licencia global exclusiva en 2024 para los derechos de desarrollo, fabricación y comercialización.
Silo Pharma (나스닥: SILO)는 콜롬비아 대학교로부터 독점 라이선스를 받은 알츠하이머 치료제 SPC-14에 대해 USPTO에 특허 출원을 제출했습니다. '알츠하이머병 및 기타 신경퇴행성 질환 치료를 위한 조성물 및 방법'이라는 제목의 이 특허는 인지 및 신경정신 증상을 해결하기 위해 글루타메이트 수용체 NDMAR와 세로토닌 5-HT4를 표적으로 하는 신약의 새로운 작용 기전을 포함합니다.
이 화합물은 초기 전임상 연구에서 황체형성호르몬에 대해 학습된 무기력, 반복 행동, 신물 회피 감소에 효과를 입증했습니다. SPC-14는 콜롬비아 대학교와의 후원 연구 계약을 통해 개발되었으며, 2024년에 개발, 제조 및 상업화 권리를 위한 독점 글로벌 라이선스 계약이 체결되었습니다.
Silo Pharma (Nasdaq : SILO) a déposé une demande de brevet auprès de l'USPTO pour SPC-14, un traitement intranasal de la maladie d'Alzheimer sous licence exclusive de l'Université de Columbia. Le brevet, intitulé « Compositions et Méthodes pour le Traitement de la Maladie d'Alzheimer et d'Autres Maladies Neurodégénératives », couvre le mécanisme novateur du médicament ciblant les récepteurs du glutamate NDMAR et de la sérotonine 5-HT4 pour traiter les symptômes cognitifs et neuropsychiatriques.
Le composé a démontré une efficacité contre l'hormone lutéinisante en réduisant l'impuissance apprise, les comportements persévératifs et l'hyponeophagie lors d'études précliniques précoces. SPC-14 a été développé via un accord de recherche sponsorisé avec l'Université de Columbia, suivi d'un accord de licence mondiale exclusive en 2024 pour les droits de développement, de fabrication et de commercialisation.
Silo Pharma (Nasdaq: SILO) hat beim USPTO eine Patentanmeldung für SPC-14 eingereicht, eine intranasale Behandlung der Alzheimer-Krankheit, die exklusiv von der Columbia University lizenziert wurde. Das Patent mit dem Titel „Zusammensetzungen und Methoden zur Behandlung der Alzheimer-Krankheit und anderer neurodegenerativer Erkrankungen“ umfasst den neuartigen Wirkmechanismus des Medikaments, der die Glutamatrezeptoren NDMAR und Serotonin 5-HT4 anspricht, um kognitive und neuropsychiatrische Symptome zu behandeln.
Die Verbindung zeigte in frühen präklinischen Studien Wirksamkeit gegen das luteinisierende Hormon, indem sie erlernte Hilflosigkeit, perseveratives Verhalten und Hyponeophagie verringerte. SPC-14 wurde im Rahmen eines geförderten Forschungsabkommens mit der Columbia University entwickelt, gefolgt von einem exklusiven globalen Lizenzvertrag im Jahr 2024 für Entwicklungs-, Produktions- und Vermarktungsrechte.
- Patent application filed for novel Alzheimer's treatment SPC-14
- Exclusive global licensing rights secured from Columbia University
- Promising pre-clinical results in cognitive function improvement
- Novel dual-targeting mechanism of action
- Drug still in early pre-clinical stage
- No clinical trials data available yet
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.
The patent, titled “Compositions and Methods for the Treatment of Alzheimer’s Disease and Other Neurogenerative Disease,” covers SPC-14’s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD. By targeting the two receptor molecules, the drug has shown efficacy against luteinizing hormone (LH) in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety).
“Early pre-clinical studies of SPC-14 have demonstrated the drug’s potential to improve and restore cognitive memory function,” said Eric Weisblum, CEO of Silo. “The patent application for SPC-14 supports our intellectual property strategy for strong security and protection of each of our drug platforms.”
SPC-14 was developed under a sponsored research agreement with Columbia University. In 2024, Silo entered into an exclusive global license agreement with Columbia University under which it is authorized to further develop, manufacture, and commercialize the drug SPC-14.
About SPC-14
SPC-14 is a novel therapeutic that targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer’s disease. In the latest small animal preclinical study, SPC-14 was effective against LH (luteinizing hormone) stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia, a measure of anxiety.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the mechanism of action of Silo Pharma's SPC-14 for Alzheimer's treatment?
What results has SILO's SPC-14 shown in pre-clinical studies?
When did Silo Pharma acquire the license for SPC-14 from Columbia University?
What type of drug delivery system is SILO using for their Alzheimer's treatment?
